The FINANCIAL — Teva Pharmaceutical Industries, Ltd. (NASDAQ: TEVA) announced on July 13 that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Plan B One-Step emergency contraception (levonorgestrel tablet, 1.5 mg).
Now, with new Plan B One-Step, women can help prevent an unintended pregnancy after unprotected sex or contraceptive failure with just one pill in one dose. The FDA is expanding over-the-counter (OTC) access to Plan B One-Step for consumers age 17 or older; women younger than age 17 will require a prescription. The product will be available at licensed U.S. retail pharmacies within the next month.
"As a leader in women's health, we're proud to offer women this new, innovative emergency contraceptive option that builds upon the trust that women have come to know with Plan B," notes Amy Niemann, General Manager, Senior Vice President of Teva Women's Health. "Emergency contraception is more effective the sooner it's taken, and with Plan B One-Step women can now act quickly and take it right away when the unexpected happens."
Discussion about this post